George Mason University bioengineering professor Michael Buschmann and a team of scientific collaborators have devised improved lipid nanoparticle technologies to deliver mRNA that could make mRNA vaccines such as the COVID-19 vaccines less costly, with fewer side-effects and more available worldwide.
Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility in Frederick, MD to Accelerate Development of Vaccines and Antiviral Drugs
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development (R&D) facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.
Fueled by a $400,000 grant from The Rockefeller Foundation, the Black Women’s Health Imperative (BWHI), based in Washington, D.C., aims to improve vaccination rates among the African-American community through outreach programs and strategic partnerships with like-minded coalitions, including the National Caucus & Center on Black Aging (NCBA) and National Coalition of 100 Black Women (NCBW).
Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious
diseases. As COVID-19 spread, dozens of Maryland companies joined the global response.
Leading coronavirus scientist, Kizzmekia S. Corbett, to join Harvard T.H. Chan School of Public Health to continue vaccine development research
Leading coronavirus scientist Kizzmekia S. Corbett is joining Harvard Chan School as an assistant professor to continue vaccine development research.
Novavax is aiming to seek Emergency Use Authorization for its COVID-19 vaccine NVX-CoV2373 later this spring. If the U.S. Food and Drug Administration gives it the green light, the Maryland-based company could see revenue of approximately $1.8 billion in sales by the end of the year.
A panel of experts discusses the future landscape for vaccine development and future opportunities for biotech companies.
Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization Rolling reviews have commenced by FDA, MHRA, EMA and Health Canada GAITHERSBURG, Md., February 4, 2021 [….]
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.